TNNT2 and AL amyloidosis: Risk of death in patients with AL amyloidosis can be stratified using the revised Mayo staging models, including cardiac biomarkers: serum troponins (cTnT ≥ 0.025 ng/mL), NT-proBNP (≥1.800 pg/mL) and serum immunoglobulin free light chain difference (FLC-diff) ≥ 18 mg/dL) [9].